BIOMAT Database Logo BIOMAT Database Logo

Measurement of patients' bivalirudin plasma levels by a thrombelastograph ecarin clotting time assay: a comparison to a standard activated clotting time. 2006

Roger C Carroll, and Jack J Chavez, and Jeffery W Simmons, and Carolyn C Snider, and Dale C Wortham, and Stuart J Bresee, and Eli Cohen
Department of Anesthesiology, University of Tennessee Graduate School of Medicine, Knoxville, Tennessee 37920, USA.

Standard activated clotting time (ACT) tests have a poor correlation to bivalirudin levels, leading to uncertainty regarding adequate anticoagulation in percutaneous coronary intervention patients. We tested a Thrombelastograph (TEG) ecarin clotting time (ECT) assay for sensitivity to bivalirudin using blood from 80 patients undergoing interventional cardiology procedures with bivalirudin anticoagulation. This was compared to a standard Hemochron ACT assay using diatomaceous earth. With the TEG assay, the direct thrombin activator, ecarin, was used to initiate coagulation and measured as the reaction time. Plasma samples were evaluated for bivalirudin by a chromogenic assay at an independent hematological laboratory. Linear regression of the standard ACT versus bivalirudin level gave an r = 0.306 whereas the TEG ECT gave a much higher r2 = 0.746 (both P < 0.0001). The TEG ECT should prove more useful than the standard ACT for monitoring bivalirudin anticoagulation across the clinically therapeutic range.

UI MeSH Term Description Entries
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010450 Endopeptidases A subclass of PEPTIDE HYDROLASES that catalyze the internal cleavage of PEPTIDES or PROTEINS. Endopeptidase,Peptide Peptidohydrolases
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D001780 Blood Coagulation Tests Laboratory tests for evaluating the individual's clotting mechanism. Coagulation Tests, Blood,Tests, Blood Coagulation,Blood Coagulation Test,Coagulation Test, Blood,Test, Blood Coagulation
D006629 Hirudins Single-chain polypeptides of about 65 amino acids (7 kDa) from LEECHES that have a neutral hydrophobic N terminus, an acidic hydrophilic C terminus, and a compact, hydrophobic core region. Recombinant hirudins lack tyr-63 sulfation and are referred to as 'desulfato-hirudins'. They form a stable non-covalent complex with ALPHA-THROMBIN, thereby abolishing its ability to cleave FIBRINOGEN. Hirudin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013916 Thrombelastography Use of a thrombelastograph, which provides a continuous graphic record of the physical shape of a clot during fibrin formation and subsequent lysis. Thromboelastography,Thromboelastometry
D014914 Whole Blood Coagulation Time The time required by whole blood to produce a visible clot. Activated Coagulation Time, Whole Blood,Blood Coagulation Time, Whole,Coagulation Time, Whole Blood
D016014 Linear Models Statistical models in which the value of a parameter for a given value of a factor is assumed to be equal to a + bx, where a and b are constants. The models predict a linear regression. Linear Regression,Log-Linear Models,Models, Linear,Linear Model,Linear Regressions,Log Linear Models,Log-Linear Model,Model, Linear,Model, Log-Linear,Models, Log-Linear,Regression, Linear,Regressions, Linear

Related Publications

Roger C Carroll, and Jack J Chavez, and Jeffery W Simmons, and Carolyn C Snider, and Dale C Wortham, and Stuart J Bresee, and Eli Cohen
Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations.
May 2003, The American journal of cardiology,
Roger C Carroll, and Jack J Chavez, and Jeffery W Simmons, and Carolyn C Snider, and Dale C Wortham, and Stuart J Bresee, and Eli Cohen
Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration.
January 2004, Thrombosis research,
Roger C Carroll, and Jack J Chavez, and Jeffery W Simmons, and Carolyn C Snider, and Dale C Wortham, and Stuart J Bresee, and Eli Cohen
Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay.
June 1997, Thrombosis research,
Roger C Carroll, and Jack J Chavez, and Jeffery W Simmons, and Carolyn C Snider, and Dale C Wortham, and Stuart J Bresee, and Eli Cohen
Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass.
February 2003, Anesthesia and analgesia,
Roger C Carroll, and Jack J Chavez, and Jeffery W Simmons, and Carolyn C Snider, and Dale C Wortham, and Stuart J Bresee, and Eli Cohen
Comparison of two different ecarin clotting time methods.
August 2005, Journal of thrombosis and thrombolysis,
Roger C Carroll, and Jack J Chavez, and Jeffery W Simmons, and Carolyn C Snider, and Dale C Wortham, and Stuart J Bresee, and Eli Cohen
Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay.
December 2013, The Annals of pharmacotherapy,
Roger C Carroll, and Jack J Chavez, and Jeffery W Simmons, and Carolyn C Snider, and Dale C Wortham, and Stuart J Bresee, and Eli Cohen
Modified plasma-based ecarin clotting time assay for monitoring of recombinant hirudin during cardiac surgery.
February 2006, American journal of clinical pathology,
Roger C Carroll, and Jack J Chavez, and Jeffery W Simmons, and Carolyn C Snider, and Dale C Wortham, and Stuart J Bresee, and Eli Cohen
Ecarin clotting time is sensitive to heparinoids: comparison of two different techniques.
January 2001, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis,
Roger C Carroll, and Jack J Chavez, and Jeffery W Simmons, and Carolyn C Snider, and Dale C Wortham, and Stuart J Bresee, and Eli Cohen
Effects of melagatran on activated partial thromboplastin time and on ecarin clotting time in cord versus adult plasma.
November 2006, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
Roger C Carroll, and Jack J Chavez, and Jeffery W Simmons, and Carolyn C Snider, and Dale C Wortham, and Stuart J Bresee, and Eli Cohen
[Follow-up of the treatment by direct thrombin inhibitors: activated partial thromboplastin time or ecarin clotting time].
January 2000, Annales de biologie clinique,
Copied contents to your clipboard!